a16z Podcast

Psychedelics: Striking a Balance Between Benefits and Side Effects

Jan 23, 2021

The podcast delves into the evolving view of psychedelics from recreational highs to serious treatments for mental health issues like depression and addiction. It discusses a promising non-hallucinogenic derivative of Ibogaine, showcasing its potential benefits while addressing safety concerns. Key insights reveal how compounds called psychoplastogens could aid in drug recovery. Moreover, it touches on the regulatory challenges that hinder research, emphasizing the necessity for a more supportive framework to explore these groundbreaking therapies.

26:19

Creator website

AI Chapters

Episode notes

Intro

2min

Psychedelic Advances in Mental Health

6min

Exploring Ibogaine and Its Derivatives

12min

Exploring Psychoplastogens: Bridging Science and Clinical Application

2min

Navigating Regulatory Hurdles in Psychedelic Research

2min

Navigating Regulatory Challenges in Psychedelic Research

2min

In recent years, there’s been a shift in how we think about psychedelics – from drugs of abuse and recreation, to powerful drugs for treating neuropsychiatric conditions such as depression, addiction, and PTSD.

But there’s still a lot we don't know about how they work, and how we can maximize their therapeutic benefits while minimizing their adverse side effects. So this episode of Journal Club discusses a method for striking that balance, from a paper published in Nature last month, “A non-hallucinogenic psychedelic analogue with therapeutic potential“... which could represent a major step forward in psychedelic medicine.

This episode first appeared on Bio Eats World:
https://a16z.com/2021/01/21/journal-club-safer-psychedelic/

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

Get the app